home About Us People Portfolio News Contact Us Fund II Investor Login » Fund III Investor Login » Fund IV Investor Login »

Avinger Inc.

$45 million

Medical Device
Cardiovascular

Jun15
2015
Avinger Announces Presentations by Key Opinion Leaders and Live Case Transmission at LINC »

Jan14
2015
Avinger Announces Closing of $7.6 Million Registered Direct Offering »

Jan11
2015
Avinger Announces 510(k) Clearance for Lightbox 3 Next-Generation Imaging Console »

Aug9
2015
Avinger Announces 510(k) Filing for New Lightbox 3 Imaging Console »

Jul6
2015
Avinger Announces 510(k) Filing for New Pantheris In-Stent Restenosis Indication »

May25
2015
Avinger Announces Issuance and Allowance of Seven U.S. Patents »

REDWOOD CITY, CA / ACCESSWIRE / May 25, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the issuance and allowance of seven U.S. patents to date in 2021.

 

These new U.S. patents include a wide range of claims relating to Avinger's proprietary optical coherence tomography (OCT) intravascular imaging system and its OCT-guided catheters for the treatment of vascular disease. With the addition of these patents and new filings made in 2021, Avinger's intellectual property portfolio now numbers 182 patents and pending applications, including 41 issued and allowed patents in the U.S. and 76 issued and allowed patents outside the U.S. The portfolio has broad applicability in the areas of atherectomy, CTO-crossing and intravascular imaging for both peripheral and coronary vessels.

 

"We continue to build our intellectual property portfolio as we expand our pipeline of proprietary products and bring new innovations and improvements to our intravascular imaging platform," commented Jeff Soinski, Avinger's President and CEO. "Our growing intellectual property portfolio supports the highly differentiated nature of our products and provides an important competitive advantage as we market the first and only intravascular OCT-guided therapeutic catheters for the treatment of vascular disease. Our proprietary technologies provide the foundation for our next-generation pipeline products, including our Lightbox 3 imaging console, anticipated to be commercially available later this year, and the development of our first coronary applications, which we believe represents a transformational opportunity for Avinger."

 

About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye™ family of chronic total occlusion (CTO) catheters, and the Pantheris® line of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

 

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our future performance, the applications of our intellectual property, the timing of commercial availability of Lightbox 3, the development of our first coronary applications, and the benefits and revenue growth opportunities of our proprietary technologies. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include the resource requirements related to Lightbox 3 and the development of our first coronary applications, the efficacy of such products, and competition from other products; as well as the other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2021, and in our Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward-looking statements, except as required by law.

 

Investor Contact:
Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

 

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

 

SOURCE: Avinger, Inc.

Apr21
2015
New Publications Highlight Clinical Benefits of Avinger PAD Therapies »

Apr8
2015
Avinger Provides Update on Tigereye(TM) Commercial Launch »

Dec4
2015
Avinger Expands Tigereye(TM) Limited Launch »

Dec1
2015
Avinger Receives Nasdaq Extension, Recommends Stockholders Vote FOR All Proxy Proposals »

Sep11
2015
Avinger Receives FDA Clearance of Ocelaris Next Generation Image-guided CTO Crossing System »

Apr30
2015
Avinger Closes $3.15 Million Equity Offering »

Aug16
2015
Avinger, Inc. Announces Closing of Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares »

Jun15
2015
Avinger, Inc. Announces Drawdown of $10 Million Under Term Loan Facility with CRG »

Dec1
2015
Avinger Announces Filing of 510(k) Application for Enhanced Version of Pantheris(TM) »

Nov2
2015
Avinger Successfully Completes VISION IDE Trial for Pantheris(TM) »

Oct14
2015
Avinger, Inc. Receives FDA 510(k) Clearance for Pantheris(TM) »

Sep23
2015
Avinger, Inc. Secures Up To $55M in Financing from CRG »